Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients

Chronic myeloid leukaemia ( CML ) arises in a haemopoietic stem cell and is driven by the B cr‐ A bl oncoprotein. A bl kinase inhibitors (protein tyrosine kinase inhibitors) represent standard treatment for CML and induce remission in the majority of patients with early disease, however these drugs do not target leukaemic stem cells ( LSC s) effectively, thus preventing cure. Previously, we identified the farnesyl transferase inhibitor BMS...